What are the CANMAT‑recommended management steps for a 48‑year‑old female with psychosis on aripiprazole (Abilify) 25 mg daily who reports low energy and reduced muscle strength?

Management of Low Energy and Reduced Muscle Strength in a Patient on Aripiprazole 25 mg

Your patient's symptoms of low energy and reduced muscle strength on aripiprazole 25 mg daily warrant immediate evaluation for secondary causes of negative symptoms, particularly medication-related side effects including extrapyramidal symptoms and sedation, followed by dose optimization within the therapeutic range.

Immediate Assessment Required

First, systematically rule out secondary causes of these symptoms, as they may represent medication side effects rather than primary negative symptoms 1:

• Evaluate for extrapyramidal symptoms (EPS): Examine for parkinsonism (bradykinesia, rigidity, tremor) which can manifest as low energy and reduced muscle strength 1
• Assess for akathisia: Inner restlessness that can present as fatigue and reduced functional capacity 1
• Screen for sedation: A known side effect that directly causes low energy 1
• Check for metabolic complications: Obtain fasting glucose, HbA1c, lipids, thyroid function (hypothyroidism), and assess for weight gain leading to sleep apnea 1
• Rule out depression: Depressive symptoms can mimic negative symptoms 1
• Evaluate positive symptom control: Persistent positive symptoms can contribute to apparent negative symptoms 1

Dose Optimization Strategy

Your patient is on 25 mg daily, which exceeds the FDA-recommended target dose and falls outside the optimal efficacy range:

• The FDA-approved target dose for schizophrenia is 10-15 mg/day 2
• Doses above 15 mg/day have not demonstrated superior efficacy compared to 10-15 mg/day 2
• The effective dose range is 10-25 mg/day, with minimal benefit above this range 3
• Consider gradual dose reduction to 15 mg/day while remaining within the therapeutic range, as this may reduce side effects including sedation and EPS without compromising efficacy 1

Management Algorithm Based on Findings

If EPS/Parkinsonism is Present:

1. Lower the aripiprazole dose to 15 mg/day or less 1
2. Consider switching to another antipsychotic if symptoms persist 1
3. Add an anticholinergic medication only if dose reduction is insufficient 1

If Akathisia is Present:

1. Reduce aripiprazole dose to 15 mg/day 1
2. Add a benzodiazepine or beta-blocker if dose reduction inadequate 1
3. Consider switching antipsychotics if refractory 1

If Metabolic Issues are Identified:

• Address cardiometabolic complications with lifestyle interventions and consider metformin if indicated 1
• Optimize sleep if sleep apnea from weight gain is contributing 1

If True Negative Symptoms Persist After Addressing Secondary Causes:

Since aripiprazole is already an appropriate choice for negative symptoms 1:

1. Optimize to 10-15 mg/day if not already at this dose 1, 2
2. Add psychosocial interventions to address negative symptoms 1
3. Consider antidepressant augmentation even without depression diagnosis, as modest benefit on negative symptoms is possible 1
4. Evaluate for cariprazine switch if negative symptoms remain predominant, though aripiprazole is already a suitable option 1

Critical Monitoring

Before any medication adjustment, ensure baseline metabolic parameters are current 1:

• BMI, waist circumference, blood pressure (weekly × 6 weeks after changes)
• Fasting glucose, HbA1c, lipids
• Liver function, renal function, complete blood count
• Prolactin level
• ECG

Key Pitfalls to Avoid

• Do not assume these are primary negative symptoms without ruling out medication side effects first 1
• Do not increase the aripiprazole dose above 25 mg—higher doses provide no additional benefit and increase side effect risk 2, 3
• Do not abruptly discontinue if switching medications; gradual cross-titration minimizes relapse risk 2
• Do not overlook subclinical EPS that may not be obvious on examination but significantly impacts quality of life 1